罗格列酮对肝癌HepG2细胞周期和凋亡的影响  

Effects of Rosiglitazone on Cell Cycle and Apoptosis of Human Hepatoma Cell Line HepG2

作　　者：康燕[1] 魏玲[1] 王永霞[1] 王立云[1] KANG Yan, WEI Ling, WANG Yongxia,et al.(The Second People＇s Hospital of Sichuan,Panzhihua,61706)

机构地区：[1]四川省攀枝花市第二人民医院,617068

出　　处：《实用癌症杂志》2018年第4期534-536,540,共4页The Practical Journal of Cancer

摘　　要：目的研究罗格列酮对人肝癌HepG2细胞周期和凋亡的影响。方法设不同浓度罗格列酮组(10、25、50.0、100.0μg/ml)、2‰二甲基亚砜的RPMI1640培养基加细胞为阴性对照组。应用MTT法检测罗格列酮对肝癌HepG2细胞的增殖抑制和生长活性,流式细胞仪检测细胞周期和凋亡。结果罗格列酮对肝癌HepG2细胞具有较强的体外毒性,48 h IC50为41.6μg/ml。肝癌HepG2细胞活性随着用药剂量和作用时间的增加而不断下降,出现剂量-效应和时间-效应的关系。罗格列酮作用48 h后,肝癌HepG2细胞G_0/G_1期比例显著升高,S期细胞比例有所降低,到G_2/M期细胞的比例明显下降,并呈明显的剂量依赖性。罗格列酮对HepG2细胞作用48 h后可以诱导肿瘤细胞产生凋亡,并且呈剂量依赖性。结论罗格列酮能抑制肝癌HepG2细胞生长并促进其凋亡。Objective To investigate the effects of rosiglitazone on cell cycle and apoptosisof human hepatoma cell line HepG2. Methods This study set up rosiglitazone different concentrations groups （10,25,50,100 μg/ml ） and negative control group （2 ‰ DMSO ＋ RPMI1640 medium ＋ cells ）. The antir proliferation effect and growth activity of rosiglitazone on human hepa- tocellular carcinoma HepG2 cells were detected by MTT method, the cell cycle and apoptosis were detected by flow cytometry. Re- sults The rosiglitazone on hepatocellular carcinoma HepG2 ceils had strong toxicity ,48 h IC50 was the 41.6 μ/ml. The growth activity decreased with the dose and time increases, showing a dose-effect relationship and time-dependent. After 48h incubation of rosiglitazone, the G0/G0 phase HepG2 cells significantly increased, S phase HepG2 cells increased, and G2/M phase HepG2 cells significantly increased, and showing a dose-effect relationship. After 48 h incubation of rosiglitazone, the rosiglitazone can induce apoptosis of tumor cells, and showing a dose-effect relationship. Conclusion Rosiglitazone can inhibit the growth of HepG2 cells and promote their apoptosis.

关 键 词：罗格列酮 人肝癌细胞株 HEPG2 细胞周期 凋亡 

分 类 号：R735.7[医药卫生—肿瘤]